SHARE THIS ARTICLE
Euflexxa
Euflexxa Manufacturer – About Ferring Pharmaceuticals
Oct 15, 2024
According to a report by MarketsandMarkets, the global knee osteoarthritis (OA) treatment market is projected to reach USD 10.1 billion by 2025, driven by the increasing prevalence of the condition and the rising demand for effective, non-surgical treatment options. Key manufacturers continuously innovate to meet patient needs, and the market is evolving rapidly.
One such leader is Ferring Pharmaceuticals, the manufacturer of Euflexxa, a 1% sodium hyaluronate solution known for improving joint lubrication and reducing knee pain. Ferring Pharmaceuticals has built a strong reputation for its dedication to improving patients’ quality of life, making it a trusted name in the knee OA treatment industry.
In this article, we will explore the background of Ferring Pharmaceuticals, their role in the knee OA treatment market, and how Euflexxa differentiates itself from other available treatments.
Key Takeaways
- Ferring Pharmaceuticals is a global leader in healthcare innovation, known for developing advanced treatments in fields like reproductive health, gastroenterology, and joint health.
- Euflexxa, one of Ferring’s flagship products, is a 1% sodium hyaluronate solution used to treat knee osteoarthritis. It was the first non-avian-derived hyaluronic acid treatment approved in the U.S. for knee OA.
- Ferring’s dedication to quality, innovation, and accessibility ensures patients can receive effective, non-surgical treatment options, enhancing their quality of life.
- Euflexxa stands out for its ability to provide long-term pain relief and improved joint function, especially for patients who haven’t found success with traditional pain management treatments.
About: Trusted by over 2,000+ global clients since 2014, Maylips has become a leading supplier of cosmetic, skincare, and orthopedic products for medical and aesthetic professionals. Maylips offers a wide range of authentic brand-name products at competitive wholesale prices, sourced from around the world. If you’re looking to buy Euflexxa online, contact our sales team for guidance.
Introduction to Ferring Pharmaceuticals
Ferring Pharmaceuticals is a global specialty healthcare company dedicated to improving patient outcomes through innovative treatments in areas such as reproductive health, gastroenterology, and orthopedics. With a strong emphasis on research and development, Ferring has become a leader in providing advanced therapies for various medical conditions, including knee osteoarthritis.

The company aims to enhance patients’ quality of life by delivering safe, effective, and innovative healthcare solutions. Ferring Pharmaceuticals is driven by a commitment to innovation, excellence in research, and patient-centric care. Their core values emphasize the following:
- Quality: Ensuring the highest standards in all of their products and treatments.
- Innovation: Continuously developing cutting-edge therapies.
- Accessibility: Collaborating with partners to make treatments like Euflexxawidely accessible to patients.
- Ethics: Prioritizing ethical practices in research, development, and distribution.
One of their notable products, Euflexxa, is a leading non-avian-derived hyaluronic acid solution approved in the U.S. for treating knee osteoarthritis. This innovative treatment offers an effective alternative for patients who haven’t found relief through traditional pain management.
History and Expertise
Ferring Pharmaceuticals was founded in 1950 by Frederik and Eva Paulsen. The company began as Nordiska Hormon Laboratoriet in Sweden, with a focus on developing peptide-based treatments. The Paulsens’ vision was to harness the potential of peptide hormones to create innovative medicines that could control key bodily processes.

Over the decades, Ferring has evolved significantly, expanding its expertise and portfolio. The company has grown from its initial focus on peptide hormones to become a global leader in reproductive medicine, maternal health, gastroenterology, and urology. Ferring’s commitment to research and development has led to the creation of life-changing treatments that support families from conception to birth and provide therapeutic solutions in various medical fields.
Ferring Pharmaceuticals has achieved numerous milestones throughout its history. Some of the notable achievements include:
- 70th Anniversary Celebration: In January 2020, Ferring celebrated its 70th anniversary, marking seven decades of innovation and impact in the pharmaceutical industry.
- Launch of Euflexxa: The company launched Euflexxa (1% sodium hyaluronate) to treat knee osteoarthritis. It helps relieve pain and improve joint function.
- Global Reach: Ferring has established a strong global presence with manufacturing facilities in several European countries and South America.
- Commitment to Sustainability: Ferring is dedicated to sustainability, ensuring responsible business practices and sustainable growth.
Commitment to Quality and Innovation
Ferring Pharmaceuticals is dedicated to quality and innovation, with a focus on improving joint health. Their product, Euflexxa, is the first non-avian-derived hyaluronic acid treatment approved in the U.S. for knee osteoarthritis. By partnering with healthcare companies, Ferring ensures affordable access to this effective treatment for patients who haven’t found relief with traditional pain management options.

Ferring continues to invest in R&D, improving the efficacy of Euflexxa and exploring new treatments for osteoarthritis. Their commitment to innovation ensures patients receive cutting-edge therapies that enhance quality of life.
Furthermore, Euflexxa is a popular treatment that is compared to other viscosupplements. In the comparison of treatments like Euflexxa vs Monovisc, Euflexxa is often chosen for its three-injection regimen, offering a gradual, consistent improvement over Monovisc’s single-injection solution. Its non-avian origin also reduces the risk of allergic reactions.
Conclusion
Euflexxa, developed by Ferring Pharmaceuticals, is a trusted and effective solution for managing knee pain caused by osteoarthritis. With a strong commitment to safety, innovation, and patient well-being, Ferring continues to lead in the development of advanced joint health treatments.
If you or someone you know is seeking lasting relief from knee pain, Euflexxa offers a proven option backed by Ferring’s dedication to quality care and cutting-edge solutions.
FAQs
1. How does Euflexxa work?
Euflexxa acts as a lubricant in the joint, helping to reduce friction and alleviate inflammation.
2. Who is a candidate for Euflexxa?
It is intended for adults with knee osteoarthritis who have not experienced sufficient relief from other treatment options.
3. How is Euflexxa administered?
Injected directly into the knee by a healthcare professional.
4. How often is Euflexxa injected?
Typically, Euflexxa is administered as a series of three injections, scheduled one week apart.
References
Osteoarthritis Therapeutics Market growth, Drivers, and Opportunities. MarketsandMarkets. https://www.marketsandmarkets.com/Market-Reports/osteoarthritis-therapeutics-market-209565994.html
Ferring Pharmaceuticals Inc. Company Information. Drugs.com. https://www.drugs.com/manufacturer/ferring-pharmaceuticals-inc-176.html